期刊文献+

Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection 被引量:4

Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection
暂未订购
导出
摘要 AIM: To determine whether local antibiotic resistance involves P-glycoprotein (Pgp)-mediated active drug outpumping during Helicobacter pylori ( H pylori) infection treatment with classic antibiotic therapy. METHODS: Pgp activity was determined in gastric mucosa biopsy specimens obtained from 53 patients with pathohistologically verified gastritis and microbiologically confirmed H pylori infection, and compared with the Pgp activity in 12 control subjects with normal endoscopic findings. TheH pylori positive patients were treated with short-term 7-d therapy consisting of two antibiotics (amoxicillin and azithromycin/metronidazole and clarithromycin) and a proton pump inhibitor. Pgp activity was determined by flow cytometry in the test of rhodamine dye efflux and quantified as mean fluorescence ratio (RMF).RESULTS: Upon the first cycle,H pylori was successfully eradicated in 20 patients, whereas therapy was continued in 33 patients. In the course of antibiotic therapy, RMF increased (P<0.05) and gastric cells showed higher rhodamine dye efflux. The mean pre-treatment RMF values were also higher (P<0.0001) in patients with multiple therapeutic failure than in those with successful H pylorieradication and control subjects.CONCLUSION: Pgp might be one of the causes of therapy failure in patients with H pylori and antibiotic therapy could be chosen and followed up on the basis of the Pgp transporter local activity. AIM: To determine whether local antibiotic resistance involves P-glycoprotein (Pgp)-mediated active drug out-pumping during Helicobacter pylori (H pylori) infection treatment with classic antibiotic therapy. METHODS: Pgp activity was determined in gastric mucosa biopsy specimens obtained from 53 patients with pathohistologically verified gastritis and microbiologically confirmed H pylori infection, and compared with the Pgp activity in 12 control subjects with normal endoscopic findings. The H pylori positive patients were treated with short-term 7-d therapy consisting of two antibiotics (amoxicillin and azithromycin/metronidazole and clarithromycin) and a proton pump inhibitor. Pgp activity was determined by flow cytometry in the test of rhodamine dye efflux and quantified as mean fluorescence ratio (RMF). RESULTS: Upon the first cycle, H pylori was successfully eradicated in 20 patients, whereas therapy was continued in 33 patients. In the course of antibiotic therapy, RMF increased (P<0.05) and gastric cells showed higher rhodamine dye efflux. The mean pre-treatment RMF values were also higher (P<0.0001) in patients with multiple therapeutic failure than in those with successful H pylori eradication and control subjects. CONCLUSION: Pgp might be one of the causes of therapy failure in patients with H pylori and antibiotic therapy could be chosen and followed up on the basis of the Pgp transporter local activity.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第18期2720-2725,共6页 世界胃肠病学杂志(英文版)
基金 Supported by Sveti Duh General Hospital, Zagreb, Croatia, approval, No. UR/P-10/1998
关键词 H pylori RMF PGP P-醣蛋白 药物转换 幽门螺杆菌 传染病
  • 相关文献

参考文献33

  • 1European Helicobacter pylori Study Group.Current European concepts in the management of Helicobacter pylori infection.The Maastricht Consensus Report.Gut 1997;41:8-13.
  • 2Malfertheiner P,Megraud F,O’Morain C,Hungin AP,Jones R,Axon A,Graham DY,Tytgat G.Current concepts in the management of Helicobacter pylori infection.The Maastricht 2—2000 Consensus Report.European Helicobacter pylori Study Group.Aliment.Pharmacol Ther 2002;16:1 67-80.
  • 3Geo。gopoulos SD,Ladas SD,Karatapanis S,Mentis A,Spiliadi C,Artikis V,Raptis SA.Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole.amoxicillin and clarithromycin.Dig Dis Sci 2000;45:63—67.
  • 4Megraud F.Resistance of Helicobacter pylori.In:Scarpignato C,Bianchi Porro G,Volume eds.Clinical pharmacology and therapy of Helicobacter pylori infection.Prog Basic Clin Pharmacol.Basel:Karger 1999;11:329—352.
  • 5van der Hulst RWM,Tytgat GNJ.Treatment of Helicobacter pylori eradication failure.In:Scarpignato C,Bianchi Porto G,Volume eds.Clinical pharmacology and therapy of Helicobacter pylori infection.Prog Basic Clin Pharmacol.Basel:Karger 1999; 11:317—328.
  • 6van Doom LJ,Schneeberger PM,Nouhan N,Plaisier AP,Quint WG,de Boer WA.Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment.Gut 2000;46:321—326.
  • 7Goodwin S.Clinical pharmacology of antimicrobials.In:Scarpignato C,Bianchi Porro G,Volume eds.Clinical pharmacology and therapy of Helicobacter pylori infection.Prog Basic Clinical Pharmacol.Basel:Karger 1999;11:76—95.
  • 8Scarpignato C,Pelosini I.Antisecretory drugs for eradication of Helicobacter pylori:antibacterial acfivity and synergism with antimicrobial agents.In:Scarpignato C,Bianchi Porro G,Volume eds.Clinical pharmacology and therapy of Helicobacter pylori infection.Prog Basic Clin Pharmacol.Basel:Karger 1999;11:136—178.
  • 9Peitz U,Menegatti M,Vaira D,Malfertheiner P.European Meeting on Helicobacter pylori:Therapeutic News from Lisbon.Gut 1998;43(Suppl 11:S66-S69.
  • 10Chiba N,Hunt RI-I.Drug therapy of Helicobacter pylori infection:a meta—analysis.In:Scarpignato C,Bianchi Porro G,Volumeeds.Clinical pharmacology and therapy of Helicobacter pylori infection.Prog Basic Clinical Pharmac01.Basel:Karger 1999;11:227—268.

同被引文献13

引证文献4

二级引证文献93

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部